Zobrazeno 1 - 10
of 26
pro vyhledávání: '"M V, Seiden"'
Autor:
M V, Seiden
Publikováno v:
The Oncologist. 6:327-332
Ovarian cancer remains the most lethal gynecologic malignancy in women in the United States. Studies from this year's American Society of Clinical Oncology more clearly defined the role of chemotherapy in women with early stage disease and now sugges
Autor:
U, Matulonis, S, Campos, L, Duska, A, Fuller, R, Berkowitz, S, Gore, M, Roche, T, Colella, H, Lee, M V, Seiden
Publikováno v:
Gynecologic oncology. 91(2)
In an effort to improve the results of primary chemotherapy for müllerian malignancies a novel chemotherapy program was piloted that delivered three sequential chemotherapy doublets. The primary endpoints were surgically defined response rates and e
Publikováno v:
Anticancer research. 22(4)
Multidrug resistance is a significant barrier to the development of successful cancer treatment. To identify genetic alterations that are directly involved in paclitaxel resistance, a functional cloning strategy was developed.Using mRNA from paclitax
Autor:
R T, Penson, J G, Supko, M V, Seiden, A F, Fuller, R S, Berkowitz, A, Goodman, S M, Campos, K M, MacNeill, S, Cook, U A, Matulonis
Publikováno v:
Cancer. 92(5)
Topotecan and paclitaxel are schedule dependent chemotherapeutic agents with activity against ovarian carcinoma. A Phase I-II study in which both drugs were administered concurrently by 96-hour, continuous, intravenous infusion was performed to deter
Autor:
D P, Ryan, J G, Supko, J P, Eder, M V, Seiden, G, Demetri, T J, Lynch, A J, Fischman, J, Davis, J, Jimeno, J W, Clark
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 7(2)
Ecteinascidin 743 (ET-743) is a cytotoxic tetrahydroisoquinoline alkaloid that covalently binds to DNA in the minor groove. The in vitro chemosensitivity of cancer cells to ET-743 is markedly enhanced by prolonging the duration of exposure to the dru
Publikováno v:
Anticancer research. 20(6B)
We have identified a novel cancer/testis antigen, TRAG-3, (Taxol Resistance Associated Gene-3) that was initially discovered in search for new genes involved in drug resistance by differential display. Early study of TRAG-3 revealed minimal to absent
Publikováno v:
Cancer. 89(2)
The high rate of incidence of skeletal complications in women with metastatic breast carcinoma appears to contribute significantly to their morbidity. Although recent trials have demonstrated the efficacy of bisphosphonates in preventing skeletal com
Autor:
D P, Ryan, T J, Lynch, M L, Grossbard, M V, Seiden, C S, Fuchs, N, Grenon, P, Baccala, D, Berg, D, Finkelstein, R J, Mayer, J W, Clark
Publikováno v:
Cancer. 88(1)
A Phase I study was initiated to determine the maximum tolerated dose of weekly gemcitabine combined with monthly, fixed-dose docetaxel.Patients with metastatic solid tumors were treated with docetaxel, 60 mg/m(2), on Day 1 every 28 days. Gemcitabine
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 5(11)
In an attempt to define the molecular changes associated with the paclitaxel-resistant phenotype in human cancer, a paclitaxel-resistant ovarian cancer cell line, SKOV-3TR, was established through stepwise selection in increasing paclitaxel concentra
Autor:
L R, Duska, R, Penson, J G, Supko, D M, Finkelstein, T, Makastorsis, J, Gallagher, K, Borden, A, Goodman, A F, Fuller, N, Nikrui, M V, Seiden
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 5(6)
A Phase I study of paclitaxel and doxorubicin administered as concurrent 96-h continuous i.v. infusion was performed to determine the maximum tolerated dose (MTD), principal toxicities, and pharmacokinetics of this combination in women with relapsed